The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Previously approved ...
DUBLIN, June 15, 2020 /PRNewswire/ -- The "MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) Drug Overview" report has been added to ResearchAndMarkets.com's offering. Sanofi's ...
The FDA has approved MenQuadfiTM Meningococcal (Groups A, C, Y, W; Sanofi Pasteur) Conjugate Vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, ...
May 30, 2025 – The FDA has approved the first-ever meningococcal vaccine for babies as young as 6 weeks old. Sanofi Pasteur’s quadrivalent MenQuadfi shot was first cleared in 2020 for adults and ...
The European Commission’s decision is based upon results from a robust and comprehensive international clinical program, including seven pivotal Phase 2 and 3 randomized, active-controlled, ...
Sanofi SNY announced that the European Commission (EC) has approved its fully-liquid meningococcal vaccine MenQuadfi for the active immunization of individuals, aged 12 months and above against ...
Dublin, June 12, 2020 (GLOBE NEWSWIRE) -- The "MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) Drug Overview" report has been added to ResearchAndMarkets.com's offering.
Please provide your email address to receive an email when new articles are posted on . The FDA has recently approved MenQuadfi, a meningococcal conjugate vaccine that protects against serogroups A, C ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback